US equities
|
SPCX
$167.05
▲+5.09%
NVDA
$237.04
▲+1.32%
MU
$1,065.52
▼-0.87%
TSLA
$375.63
▲+1.36%
MSFT
$525.88
▲+1.61%
INTC
$117.07
▼-1.89%
SNDK
$1,724.37
▲+0.25%
META
$743.02
▲+2.05%
SPCX
$167.05
▲+5.09%
NVDA
$237.04
▲+1.32%
MU
$1,065.52
▼-0.87%
TSLA
$375.63
▲+1.36%
MSFT
$525.88
▲+1.61%
INTC
$117.07
▼-1.89%
SNDK
$1,724.37
▲+0.25%
META
$743.02
▲+2.05%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Kyverna Therapeutics, Inc. - Common Stock
(NQ:
KYTX
)
6.080
-0.140 (-2.25%)
Delayed Quote
Updated: 10:51 AM EDT, Oct 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Kyverna Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
Next >
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc. (Nasdaq: KYTX); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
December 12, 2024
From
DiCello Levitt LLP
Via
GlobeNewswire
Kyverna Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Kyverna Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 7, 2025 - KYTX
December 12, 2024
Via
ACCESSWIRE
Kyverna Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 7, 2025 to Discuss Your Rights - KYTX
December 12, 2024
Via
ACCESSWIRE
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
December 12, 2024
From
Law Offices of Howard G. Smith
Via
Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
December 12, 2024
From
Glancy Prongay & Murray LLP
Via
Business Wire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 7, 2025 in Kyverna Therapeutics, Inc. Lawsuit - KYTX
December 12, 2024
Via
ACCESSWIRE
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
December 12, 2024
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
KYVERNA ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. and Encourages Investors to Contact the Firm
December 11, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of Investors
December 11, 2024
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTX
December 11, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTX
December 10, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Rosen Law Firm Urges Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
December 10, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) INVESTOR ALERT: Investors With Large Losses in Kyverna Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
December 10, 2024
From
Bernstein Liebhard LLP
Via
GlobeNewswire
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
December 10, 2024
From
The Schall Law Firm
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics
December 10, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX)
December 09, 2024
From
Scott+Scott Attorneys at Law LLP
Via
Business Wire
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
↗
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Toll Brothers Posts Strong Earnings, Joins Keysight, Coty, TJX And Other Big Stocks Moving Higher On Wednesday
↗
August 21, 2024
Via
Benzinga
Home Depot, Paysafe And 3 Stocks To Watch Heading Into Tuesday
↗
August 13, 2024
Via
Benzinga
KYTX Stock Earnings: Kyverna Therapeutics Misses EPS for Q2 2024
↗
August 12, 2024
KYTX stock results show that Kyverna Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Cell Therapy Mostly Used For Blood Cancer Shows Efficacy In Autoimmune Diseases As Well, But There Are Challenges
↗
July 19, 2024
CAR-T therapy, originally used for blood cancers, shows promising results in treating lupus, as evidenced by Janina Paech's remarkable remission. This breakthrough offers new hope for autoimmune...
Via
Benzinga
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
↗
July 16, 2024
Via
Benzinga
Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session
↗
June 14, 2024
Via
Benzinga
KYTX Investors Have Opportunity to Join Kyverna Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
June 14, 2024
From
The Schall Law Firm
Via
Business Wire
Why Kyverna Therapeutics Stock Is Sinking
↗
June 14, 2024
Kyverna Therapeutics shares are falling Friday. The company released a presentation on KYV-101, its CD19 CAR T-cell candidate. Here's a look at the details:
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
↗
June 14, 2024
Via
Benzinga
Dow Tumbles Over 200 Points; Adobe Earnings Top Views
↗
June 14, 2024
Via
Benzinga
Topics
Stocks
Why Signet Jewelers Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
June 13, 2024
Via
Benzinga
Tesla, Nvidia, John Wiley & Sons And Other Big Stocks Moving Higher On Thursday
↗
June 13, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
June 03, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
